Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial infusion of irinotecan liposome (II) + oxaliplatin + 5-fluorouracil/leucovorin in pancreatic cancer
ChiCTR2500111898Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome, oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC), sponsored by Union Hospital. Primary endpoint: objective response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomeoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500111898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111898.